Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab vs Oral Hormone for Refractory Chronic Rhinosinusitis
NCT05390255Phase 3Unknown
- Sponsor
- Beijing Tongren Hospital
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in chronic rhinosinusitis (CRS), sponsored by Beijing Tongren Hospital. Status: unknown.
02
Drugs
omalizumab
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT05390255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05390255.